Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Journal of the American College of Cardiology|June 21, 2023
Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes MellitusDavid D Berg, Filipe A Moura, Andrea Bellavia, et al.
BBA Clinical|December 18, 2015
Low zinc levels is associated with increased inflammatory activity but not with atherosclerosis, arteriosclerosis or endothelial dysfunction among the very elderlyRafaela C S De Paula, Ehimen C Aneni, Ana Paula R Costa, et al.
European Heart Journal|January 19, 2025
Skeletal muscle adiposity, coronary microvascular dysfunction, and adverse cardiovascular outcomesAna Carolina do A H Souza, Amelie S Troschel, Jan P Marquardt, et al.
Atherosclerosis|September 20, 2015
Glycosylated hemoglobin is associated with decreased endothelial function, high inflammatory response, and adverse clinical outcome in non-diabetic STEMI patientsFilipe A Moura, Valeria N Figueiredo, Bruna S B S Teles, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 14, 2019
Reciprocal Multifaceted Interaction Between HDL (High-Density Lipoprotein) and Myocardial InfarctionAndrei C Sposito, José Carlos de Lima-Junior, Filipe A Moura, et al.
The New England Journal of Medicine|September 1, 2025
Targeting APOC3 with Olezarsen in Moderate HypertriglyceridemiaBrian A Bergmark, Nicholas A Marston, Thomas A Prohaska, et al.
Cardiovascular Diabetology|March 27, 2026
Dapagliflozin-induced integrated improvements in left ventricular diastole, endothelial function, and arterial load: a randomized clinical trialSheila T Kimura-Medorima, Daniela C Oliveira, Ikaro Breder, et al.
Circulation Research|January 15, 2026
A Road Map to Understanding Cardiovascular Disease in Diabetes: From the AHA Strategically Focused Research Network in Cardiometabolic Health and Type 2 DiabetesE Dale Abel, Rexford S Ahima, Ethan J Anderson, et al.
Cardiovascular Diabetology|March 27, 2021
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trialAndrei C Sposito, Ikaro Breder, Alexandre A S Soares, et al.
Cardiovascular Diabetology|August 6, 2022
Evolocumab on top of empagliflozin improves endothelial function of individuals with diabetes: randomized active-controlled trialAndrei C Sposito, Ikaro Breder, Joaquim Barreto, et al.
Pageof 5